The calcium-sensing-receptor agonist, AMG 416, has previously been shown to lower plasma parathyroid hormone levels in uraemic animals and in healthy individuals. Now, researchers report that treatment with the agent was well tolerated and resulted in dose-dependent decreases in the levels of serum parathyroid hormone, fibroblast growth factor 23 and serum calcium in 28 patients with secondary hyperparathyroidism on haemodialysis. They conclude that AMG 416 therapy may be a novel way of treating secondary hyperparathyroidism in haemodialysis patients.